Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of JST-010 in Healthy Adults
NCT06943378Phase 1Active, not recruiting
- Sponsor
- Evotec SE
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pneumonic plague comparing JST-010 with Placebo (2 arms). Primary endpoint: Safety and tolerability of a single dose of JST-010 at Week 48. Started May 2025; status: active, not recruiting.
02
Drugs
JST-010
03
Conditions
pneumonic plague
Beyond the preview
Go deeper on NCT06943378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943378.